At the therapeutic level, combining LDH inhibitors (e.g. oxamate) with epigenetic drugs (e.g. DNMT inhibitors) may block Cs+ HCC progression, although challenges such as persistent parasitic infection require further investigation. The gene discussed is CS; the disease is hepatocellular carcinoma.